Citrate anticoagulation during CVVH in high risk bleeding patients

International Journal of Artificial Organs

Volumn 30, Issue 3, 2007, Pages 244-252

  Cubattoli, Lucia ^a   Teruzzi, M ^a   Cormio, M ^a   Lampati, L ^a   Pesenti, A ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Acute renal failure; Bleeding complications; Citrate toxicity; Hemofiltration; Trisodium citrate

Indexed keywords

BLOOD; CALCIUM; HEMODYNAMICS; INTENSIVE CARE UNITS; PATIENT TREATMENT;

ACUTE RENAL FAILURE; ANTI-COAGULATION; BLEEDING COMPLICATION; BLEEDINGS; BLOOD FLOW; CALCIUM CONCENTRATION; CITRATE TOXICITY; HEMOFILTRATION; RENAL FAILURE; TRI-SODIUM CITRATES;

TOXICITY;

CALCIUM CHLORIDE; CALCIUM ION; CITRATE TRISODIUM; DIALYSIS FLUID; GLUCONATE CALCIUM; HEPARIN;

ACID BASE BALANCE; ADULT; AGED; ALKALOSIS; ANTICOAGULATION; ARTICLE; BLEEDING; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERNATREMIA; HYPOCALCEMIA; KIDNEY FAILURE; MALE; MEDICATION ERROR; THROMBOSIS;

EID: 34248402534     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703000310     Document Type: Article

References (38)

1. Clark WR, Alaka KJ, Mueller BA, Macias WL. A comparison of metabolic control by continuous and intermittent therapies in acute renal failure. J Am Soc Nephrol 1994; 4: 1413-20.
2. Van de Wetering J, Westendorp R, Stolk B, et al. Heparin use in continuous renal replacement procedures: The struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7:145-50.
3. Samuelsson O, Amiral J, Attman PO, Bennegard K, Bjorck S, Larsson G, Tengborn L. Heparin-induced thrombocytopenia during continuous haemofiltration. Nephrol Dial Transplant 1995; 10: 1768-71.
4. Mehta RL, McDonald BR, Anguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialisis in critically ill patients. Kidney Int 1990; 38: 976-81.
5. Ward DM, Metha PL. Extracorporeal managment of acute renal failure patients at high risk if bleeding. Kidney Int 1993; 43 (suppl 41): S237-44.
6. Hory B, Cachoux A, Toulemonde F. Continuous arteriovenous hemofiltration with low-molecular-weight heparin. Nephron 1985; 41: 125.
7. Ponikvar R, Kandus A, Buturovic J, Kveder R. Use of prostacyclin as the only anticoagulant during continuous veno-venous hemofiltration. Contrib Nephrol 1991; 93: 218-20.
8. Ohtake Y, Hirasawa H, Sugai T, et al. Nafamostat mesilate as anticoagulant in continuous hemofiltration and hemodiafiltration. Contrib Nephrol 1991; 93: 215-7.
9. Ward D. The approach to anticoagulation in patients treated with extracorporeal therapy in the intensive care unit. Adv Ren Replace Ther 1997; 4: 160-73.
10. Kaplan AA, Petrillo R. Regional heparinization for continuous arteriovenous hemofiltration. Trans Am Soc Artif Intern Organs 1987; 33: 312-5.
11. Oudemans-van Straaten HM, Wester JP, de Pont AC, et al. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 2006; 32: 188-202.
12. Morabito S, Guzzo I, Solazzo A, et al. Continuous renal replacement therapies: Anticoagulation in the critically ill at high risk of bleeding. J Nephrol 2002; 16: 566-71.
13. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55: 1991-7.
14. Kutsogianns DJ, Meyers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2000; 35: 802-11.
15. Manns M, Sigler M, Teehan B. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 32: 185-207.
16. Tolwani AJ, Campbell RC, Schenk MB, et al. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60: 370-4.
17. Monchi M, Berghmans D, Ledoux D, et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-5.
18. Kutsogiannis DJ, Gibney RTN, Stollery D, et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-7.
19. Bohler J, Schollmeyer P, Dressel B, et al. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996; 7: 234-41.
20. Mitchell A, Daul A.E, Beiderlinden M, et al. A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD). Clin Nephrol 2003; 59: 106-14
21. Samek V, Novak L, Matejovic M, et al. Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of patient with acute renal failure, hypercalcemia and trombocytopenia. Intensive Care Med 1998; 24: 262-4.
22. Cointault O, Kamar N, Bosies P, et al. Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial solutions. Nephrol Dial Transplant 2004; 19: 171-8.
23. Hofmann RM, Maloney C, Ward DM, et al. A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF). Ren Fail 2002; 24: 325-35.
24. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26: 1652-7.
25. FDA issues warning on tricitrasol dialysis catheter anticoagulant. Talk paper. Apr 2000. http://www.fda.gov/bbs/topics/ANSWERS/ANS01009.html
26. Flanigan MJ, Pillsbury I, Sadewasser G, et al. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney Dis 1996; 27: 519-24.
27. Meier-Kriesche HU, Finkel KW, Gitomer JJ, DuBose TD. Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Am J Kidney Dis; 1999; 33: e8.
28. Van Bommel EF, Hesse CJ, Jutte NHPM et al. Cytokine kinetics (TNF-alfa, IL-1beta, IL-6) during continuous hemofiltration: a laboratory and clinical study. Contrib Nephrol 1995; 116: 62-75.
29. Ronco C, Tetta C, Lupi A, et al. Removal of platelet-activating factor in experimental continuous arteriovenous hemofiltration. Crit Care Med 1995; 23: 99-107.
30. Diaz J, Acosta F, Parrilla P, et al. Correlation among ionized calcium, citrate and total calcium levels during hepatic transplantation. Clin Biochem 1995; 28: 315-7.
31. Cotè CJ, Drop LJ, Hoaglin DC, et al. Ionized hypocalcemia after fresh frozen plasma administration to thermally injured children: effect of infusion rate, duration and treatment with calcium chloride. Anesth Analg 1988; 67: 152-60.
32. Diaz J, Acosta F, Martinez P, Parrilla P. [Treatment of ionic hypocalcemia during hepatic transplantation] [Article in Spanish]. Med Clin (Barc) 1994; 103: 118-9.
33. Denlinger JK, Nahrwold ML, Gibbs PS, Lecky JH. Hypocalcemia during rapid blood transfusion in anaesthetized man. Br J Anaesth 1976; 48: 995-1000.
34. Ladenson JH, Miller WV, Sherman LA. Relationship of physical symptoms, ECG, free calcium, and other blood chemistries in reinfusion with citrated blood. Transfusion 1978; 18: 670-9.
35. Nakasone N, Watkins E Jr, Janeway CA, Gross RE. Experimental studies of circulatory derangement following the massive trasfusion of citrated blood. J Lab Clin Med 1954; 43: 184-95.
36. Dorval M, Madore F, Courteau S, Leblanc M. A novel citrate anticoagulation regimen for continuous hemofiltration. Intensive Care Med 2003; 29: 1186-9.
37. Calatzis A, Toepfer M, Schramm W, et al. Citrate antiocoagulation for extracorporeal circuits: effect on whole blood coagulation activation and clot formation. Nephron 2001; 89: 233-6.
38. Gabutti L, Marone C, Colucci G, et al. Citrate anticoagulation in continuous venovenous hemofiltration: a metabolic challenge. Intensive Care Med 2002; 28: 1419-25.